Joint Action on Chronic Diseases Kicks Off

Representatives from over 60 European health organisations gather in Spain this week to kick-off the Joint Action addressing chronic diseases and promoting healthy ageing across the life-cycle, CHRODIS-JA, in short.

A Joint Action (JA) is an initiative undertaken by the EU, Member States and/or competent authorities of countries participating in the EU's Health Programme. CHRODIS-JA brings together participants from across Europe in order to exchange good practices across Europe, specifically looking at health promotion and prevention. The launch of the JA follows a reflection process of the European Commission and Member States on chronic conditions, as well as the work done in the Active and Healthy Ageing Innovation Partnership.

At the end of last year, on World Diabetes Day, European Health Commissioner Borg announced that special focus will be given to diabetes in the Commission's work on chronic diseases. An EU Summit dedicated to chronic diseases will take place in April - the Joint Action, and diabetes, will feature heavily on the Summit's programme.

From an operational point of view, the JA works with four work packages. There are three work packages focusing on:

  • Health promotion and disease preventionTaking Meds.JPG
  • Multi-morbidity
  • Diabetes

A fourth work package works across these themes and is entitled a Platform for Knowledge Exchange. Finally, representatives of the national ministries of health meet in a specific Forum in CHRODIS-JA. The expected outcomes of the JA include practical measures such as a special training programme designed for health professionals to deal with multi-morbidity, and a set of best practices on early detection and patient empowerment programmes. It is also expected that national programmes on diabetes will be reviewed during this JA.

Lilly certainly welcomes the EU initiative as it brings together experts to address the challenge that Europe is facing with regard to chronic diseases. This is really necessary, diabetes for example affects 382 million people worldwide, a number that is expected to go up to 592 million by 2035.

Here at Lilly, we have been committed to diabetes for over 90 years. Last year we celebrated the anniversary of insulin availability. Read more on Lilly's activities in our previous blogs on diabetes.